AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2021
Nov 15, 2021
35334_dirs_2021-11-15_e5bbaa5d-64a2-4aa3-9d0f-1ba3a91aeead.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AIM ImmunoTech Inc. (AIM)
CIK: 0000946644
Period of Report: 2021-11-11
Reporting Person: EQUELS THOMAS K. (Director, CEO & President)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-11-11 | Options | $1.71 | A | 300000 | Acquired | 2031-11-11 | Common Stock (300000) | Direct |
More from AIM ImmunoTech Inc.
Capital/Financing Update
2026
Jun 8
Report Publication Announcement
2026
Jun 4
Capital/Financing Update
2026
May 21
Capital/Financing Update
2026
May 21
Share Issue/Capital Change
2026
May 19
Capital/Financing Update
2026
May 19
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 14
Capital/Financing Update
2026
May 12
Capital/Financing Update
2026
May 8